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Abstract
Ovalbumin (OVA) genetically fused to protein sigma 1 (ps1) results in tolerance to both OVA and ps1. Ps1 binds in a multi-
step fashion, involving both protein- and carbohydrate-based receptors. To assess the relative ps1 components responsible
for inducing tolerance and the importance of its sialic binding domain (SABD) for immunization, modified OVA-ps1, termed
OVA-ps1(short), was deleted of its SABD, but with its M cell targeting moiety intact, and was found to be
immunostimulatory and enhanced CD4
+ and CD8
+ T cell proliferation. When used to nasally immunize mice given with
and without cholera toxin (CT) adjuvant, elevated SIgA and serum IgG responses were induced, and OVA-ps1(s) was more
efficient for immunization than native OVA+CT. The immune antibodies (Abs) were derived from elevated Ab-forming cells
in the upper respiratory tissues and submaxillary glands and were supported by mixed Th cell responses. Thus, these studies
show that ps1(s) can be fused to vaccines to effectively elicit improved SIgA responses.
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Introduction
A number of strategies have been developed to improve
parenteral and mucosal vaccine uptake, particularly those that
adapt adhesins. Original strategies involved the coupling of
vaccines to anti-Ig antibodies (Abs) [1] or MHC class II
molecules [2] to develop an adjuvant-free method to enhance
vaccine uptake. More recently, using Abs to target dendritic cells
(DCs), as with DEC205 mAb, has enhanced immunogenicity to
HIV [3] and plague LcrV [4]. Likewise, using a mAb to C-type
lectin DC-specific intracellular adhesion molecule 3-grabbing
nonintegrin has been used to stimulate human DCs in vitro from
volunteers previously immunized with KLH-pulsed DCs [5].
Alternatively, using poly-c-glutamic acid-based nanoparticles
has also been used to effectively target DCs’ phagocytic pro-
perties following parenteral immunization to stimulate proin-
flammatory responses that could ultimately protect against
Listeria monocytogenes challenge [6]. Even small peptides, as shown
using a 12-mer peptide, have been found to bind human DCs
and when fused to Bacillus anthracis protective antigen, it
facilitates antigen (Ag) uptake more effectively than without
the DC-targeting peptide for conferring protection against B.
anthracis Sterne challenge [7].
Both the described Ab- [1–5] and DC-targeting methods [3–
7] adopt a targeting strategy for a specific host cell receptor. To
improve mucosal immunity, strategies also have focused on
targeting microfold (M) cells [8], a specialized epithelium
present on the luminal surface of the Peyer’s patches (PPs) or
nasal-associated lymphoid tissue (NALT). M cells can sample
l u m i n a lA g so r ,i ns o m ec a s e s ,a r et a r g e t e db yi n t e s t i n a l
pathogens [9,10]. Consequently, M cells have been targeted to
facilitate uptake of DNA vaccines using M cell ligands [11–13],
including reovirus protein sigma one (ps1) [11,12], an anti-M
cell mAb [14], or the B subunit for cholera toxin (CT-B) [15–
19].
Because of its ability to bind to tissue M cells [20–24], we
questioned whether ps1could be adapted to deliver soluble Ags
to the mucosa. Ps1 is a highly structured protein composed of
an elongated fibrous tail (T), which inserts into the virion, and a
globular head (H), which protrudes from the virion to bind host
cells. Ps1 is subdivided into five distinct morphologic domains:
T1 to T4 and H. The T1 domain, ,25 residues long, forms an
a-helical coiled-coil and turn; T2, ,150 residues long, forms an
a-helical coiled-coil, referred to as the shaft; T3, ,65 residues,
is an eight stranded b-sheet containing a sialic acid binding
domain (SABD); and T4, ,75 residues, contains the trimerizing
domain and consists of a b-sheet structure flanked by two short
regions of a-helical coiled-coil [21]. Finally, the H domain or
head, ,145 residues, is believed to assume a globular structure,
as evidenced by electron microscopy and by its crystal structure
[22]. Previous work has elegantly demonstrated that ps1
mediates a multi-step adhesion process involving both protein-
and carbohydrate-based receptors [23]. At least one cell
receptor has been identified as the junction adhesion molecule
1 (JAM-1) [24].
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ps1 have proven successful in eliciting tolerance to OVA [25–27],
proteolipid protein peptide [27], and myelin oligodendrocyte
glycoprotein (MOG; [28,29]). In fact, nasal or oral MOG-ps1
treatment could reverse experimental autoimmune encephalomy-
elitis within 24 h of intervention [28,29]. Ps1 is self-tolerizing,
allowing multiple doses if required [25], and it tolerizes passenger
tolerogens, even in the presence of potent adjuvants CT and CpG
[25]. Because of ps1’s capacity to induce tolerance to physically
coupled proteins, we queried the relevance of ps1’s SABD to
tolerance and immunity. Previous studies have established the
importance of ps1’s H to L cell [30,31] and M cell binding
[11,20,26,32], and thus, a mutant ps1 was generated, lacking its
SABD, but still retaining its H to maintain its targeting capabilities
(Figure 1A). As a result, when ovalbumin (OVA) was genetically
coupled to mutant ps1, termed OVA-ps1(short) [OVA-ps1(s)],
the ability to induce tolerance to OVA was abrogated. Instead,
immunization occurred, and in fact, in the presence of co-
administered adjuvant, OVA-ps1(s) was 5-fold more effective per
molar basis in stimulating anti-OVA Ab titers than native OVA.
These results suggest that retention of ps1’s H was sufficient to
improve OVA’s immunogenicity.
Results
Differential cell binding activity in the absence of Ps1’s
SABD
Previous work with OVA-ps1 demonstrates it could induce
tolerance to OVA when given nasally [25] or orally [26], and M
cell uptake of OVA-ps1 contributes to this tolerogenic response
[25,26]. Since others have shown that reovirus binding to host cells
is a two-step process via ps1’s SABD and H [23], we queried
whether ps1’s ability to stimulate tolerance is in part contributed
to sialic acid binding. Thus, we hypothesized ps1 could be further
manipulated to direct an inflammatory rather than a tolerogenic
response and still retain its ability to direct vaccines via its globular
H to mucosal inductive tissues via M cells. To enable vaccination,
ps1 was truncated to eliminate its shaft and SABD, leaving the
trimerization domain and head intact (Figure 1A) to allow the
latter to mediate M cell binding [20]; the new truncated construct
was termed ps1(short) [ps1(s)] (Figure 1A). To demonstrate the
cell binding properties of ps1(s), GFP-ps1 and GFP-ps1(s) were
generated to facilitate detection by flow cytometry. As previously
shown [23,30,31], intact ps1 bound to both L and HeLa cells
(Figure 1B). While still retaining its ability to bind to L cells, GFP-
Figure 1. Deletion of ps1’s sialic acid binding domain (SABD) eliminates HeLa cell binding capacity. A. Schematic representation of
OVA-ps1 variants: tolerogenic OVA-ps1 (shaft, SABD, trimerization domain [trimer], and head) and OVA-ps1(short) [OVA-ps1(s)] lacking the SABD
and shaft. Cell binding to L929 cells, HeLa cells, and dendritic cells by recombinant B. GFP-ps1, C. GFP-ps1(s), and D. GFP are shown. GFP-ps1(s)
bound to L929 cells and to mouse DCs, but lost capacity to bind HeLa cells (sialic acid-dependent).
doi:10.1371/journal.pone.0036182.g001
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ps1 bound to DCs, but GFP-ps1(s) showed reduced binding
capacity to DCs, suggesting a portion of its binding interactions is
sialic acid binding-dependent (Figure 1D). Collectively, these results
demonstrate that ps1(s) can retain its ability to bind to L cells via its
H domain, but not to HeLa cells since its SABD is absent.
Ps1(s) retains ability to bind M cells
Wehavepreviouslyshownintact ps1 iscapableofbinding to host
PP [26] and NALT M cells [11]. The L cell binding data suggest
ps1(s) binding is primarily mediated via the H and is less dependent
upon the SABD. To determine if OVA-ps1(s) retains the ability to
bind to M cells, an ileal loop assay was performed. Segments of small
intestine were incubated with OVA or OVA-ps1(s) for 1 hr and
subsequently evaluated by immunofluorescence for their ability to
bind to PP M cells (Figure 2). Using an anti-OVA Ab, OVA-ps1(s)
co-localized to PP M cells with FITC-UEA-1 (Figure 2C, D) similar
to that seen with intact ps1 [26], but in mouse intestinal loops
incubated with OVA, no co-localization with FITC-UEA-1 was
observed (Figure 2B). Thus, these data show OVA-ps1(s) can still
target host M cells in the absence of its SABD, suggesting vaccines
can still be delivered to mucosal inductive tissues.
Absence of SABD by Ps1(s) stimulates, rather than
inhibits, CD4
+ and CD8
+ T cells to OVA
To test if OVA-ps1(s) was tolerogenic or immunostimulatory,
transgenic DO11.10 CD4
+ (Figure 3 A) and OT-1 CD8
+ T cells
(Figure 3B) were cultured in the presence of Ag-pulsed DCs. These
DCs were given 50 mg/ml OVA-ps1, 50 mg/ml OVA-ps1(s),
50 mg/ml OVA, or 1.0 mg/ml OVA overnight, washed, and co-
cultured with CFDA-labeled DO11.10 or CFDA-labeled OT-I T
cells for 4 days. Both OVA and OVA-ps1(s) induced DO11.10
CD4
+ and OT-I T cell proliferation, whereas OVA-ps1 did not
(Figure 3), suggesting OVA-ps1(s) is immunostimulatory.
Nasal OVA-ps1(s) stimulates elevated Ab responses in
the presence or absence of adjuvant
To learn OVA-ps1(s)’s immunogenicity, a dose response and
kinetic analysis were performed with groups of C57BL/6 mice
nasally immunized with 10, 30, or 100 mg OVA-ps1(s) with
(Figure 4A–C) or without CT adjuvant (Figure 4D–F). Serum IgG
anti-OVA end point titers were rapidly induced after the second
(100 mg-dosed mice) or third immunization with OVA-ps1(s)
(30 mg-dosed mice), when given with CT, with an endpoint titer as
great as 2
1960.58 (Figure 4A). Serum IgA anti-OVA titers were
delayed for all groups and not detectable until after day 21, but
these continued to increase to day 42 post-primary immunization
(Figure 4B). In the absence of co-administered CT, serum IgG
anti-OVA Abs were still greatly induced with the 30 mg OVA-
ps1(s) peaking at 2
16.761.39 (Figure 4D), but showed a reduced
serum IgA response although better than mice dosed with 10 mgo r
100 mg (Figure 4E; P,0.05). Mucosal IgA anti-OVA Ab titers
were potentiated in the presence of CT evidenced by the enhanced
fecal IgA responses with either 30 or 100 mg dose (Figure 4C)
when compared to mice immunized with 30 mg OVA-ps1(s) alone
with mucosal IgA Ab titers of 2
4.3 (Figure 4F). In either the
presence (Figure 4A–C) or absence of CT (Figure 4D–F), mice
immunized with OVA-ps1 failed to elicit appreciable serum IgG,
IgA, or mucosal IgA anti-OVA responses consistent with our
previous reports that OVA-ps1 induces Ag-specific unresponsive-
ness [22,23]. Thus, these results show OVA-ps1(s) can induce
both systemic and mucosal Ab responses to ferried OVA, unlike
OVA-ps1, and these responses are potentiated in the presence of
co-administered adjuvant.
Nasal OVA-ps1(s) immunization lessens the amount of
vaccine required for immunization
Similar to that done with OVA-ps1(s), a dose and kinetic
analysis was also performed to determine how effective 30 or
Figure 2. OVA-ps1(s) retains the ability to bind PP M cells. An
ileal loop assay was performed to assess the ability of OVA-ps1(s) and
OVA to bind to PP M cells as determined by co-localization with FITC-
UEA-1. A. Fucose block of UEA-1 binding in the presence of biotinylated
rabbit IgG and Streptavidin-AlexaH Fluor 594. B. OVA does not co-
localize to PP M cells since no OVA could be detected with biotinylated
rabbit anti-OVA plus Streptavidin-AlexaH Fluor 594. C. and D. OVA-
ps1(s) co-localizes with UEA-1 in PP M cells as detected with
biotinylated rabbit anti-OVA plus Streptavidin-AlexaH Fluor 594 at C.
2006and D. 6006.
doi:10.1371/journal.pone.0036182.g002
Figure 3. OVA-ps1(s) is immunostimulatory and can induce
transgenic DO11.10 CD4
+ and OT-I CD8
+ T cells to proliferate.
Naive DCs were isolated and pulsed with media, 50 mg/ml, 1.0 mg/ml
OVA (206), 50 mg/ml OVA-ps1(s), or 50 mg/ml OVA-ps1, for 24 hrs and
co-cultured with carboxy-fluorescein diactetate succinimidyl ester
(CFDA)-labeled, purified A. DO11.10 CD4
+ or B. OT-I CD8
+ T cells for
4 days. Extent of T cell proliferation was measured by flow cytometry.
Depicted are the mean 6 SEM of two - three experiments: * P,0.001 vs.
media;
" P,0.001 vs. OVA (206);
{ P#0.002 vs. OVA-ps1.
doi:10.1371/journal.pone.0036182.g003
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35 days post-primary immunization, mice immunized with 30 or
100 mg OVA, in the absence of CT, showed similar serum IgG Ab
titers, as did mice nasally immunized with OVA plus CT (Figure
S1A). Likewise, OVA plus CT-immunized showed no significant
differences in serum IgA anti-OVA titers, and low serum IgA titers
were obtained in mice immunized with OVA alone (Figure S1B).
For SIgA responses, CT adjuvant was required and optimally
induced by mice immunized with the 100 mg OVA plus CT
(Figure S1C–D). Thus, given these findings, mice evaluated in
subsequent experiments used the 100 mg OVA plus CT dose.
Although the results obtained from mice immunized with a 30
or 100 mg OVA-ps1(s) dose produced similar responses, it
appeared the 30 mg dose was sufficient to stimulate a potent Ab
response in the presence of CT. To test the effectiveness of OVA-
ps1(s) as an immunogen relative to OVA, groups of mice were
nasally immunized with 30 mg OVA-ps1(s) alone or with CT and
another group with 100 mg OVA+CT (optimal dose of OVA).
Both groups of mice adjuvanted with CT showed similar serum
IgG anti-OVA Ab titers, and even mice immunized with OVA-
ps1(s) alone showed elevated Ab titers, but significantly less
(P,0.001) than the adjuvanted groups (Figure 5A). Serum IgA Ab
titers mimicked serum IgG responses, although OVA-ps1(s) plus
CT-dosed mice showed sustained IgA Ab titers when compared to
OVA plus CT-dosed mice (P#0.001; Figure 5B). Fecal IgA Ab
titers for both the 30 mg OVA-ps1(s) plus CT-dosed and 100 mg
OVA plus CT-dosed mice were similar, and the addition of CT
clearly potentiated the mucosal IgA response when compared to
mice dosed with OVA-ps1(s) alone (Figure 5C). Nasal wash data
revealed no significant differences in IgG or IgA Abs among CT-
adjuvanted groups, but these were significantly different (P,0.001)
from mice given OVA-ps1(s) alone (Figure 5D). Collectively, these
Figure 4. Nasal OVA-ps1(s) stimulates Ab responses, unlike OVA-ps1. C57BL/6 mice were nasally vaccinated with OVA-ps1(s) or OVA-ps1
plus A.–C. adjuvant or D.–F. without adjuvant, and OVA-specific A. and D. serum IgG, B. and E. serum IgA, and C. and F. fecal IgA Ab responses
were measured. C57BL/6 mice (5/group) were dosed nasally with 10, 30, or 100 mg OVA-ps1(s) or with 100 mg OVA-ps1 with or without CT on days 0,
7, and 14. A kinetic analysis of the indicated time points is depicted as endpoint Ab titers from one of three experiments as mean 6 SEM.
doi:10.1371/journal.pone.0036182.g004
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responses to OVA more efficiently by ,5-fold on a molar basis
than native OVA.
IgG subclass responses induced in OVA-ps1(s) plus CT-
immunized mice relative to OVA plus CT-immunized mice were
significantly enhanced (P,0.001) at both 21 and 28 days post-
primary immunization. IgG1 titers were slightly, but significantly,
elevated when compared to OVA plus CT-immunized mice
(Figure 6A). Serum IgG2a anti-OVA Ab titers by OVA-ps1(s)
plus CT-immunized mice were elevated 34- and 158-fold on days
21 and 28, respectively, when compared to OVA plus CT-
immunized mice (P,0.001; Figure 6B). Likewise, IgG2b anti-
OVA Ab titers were significantly enhanced (P,0.001) by ,30-fold
versus OVA plus CT-immunized mice on days 21 and 28
(Figure 6C). Interestingly, even in the absence of adjuvant, OVA-
ps1(s)-immunized mice showed significantly greater IgG2a and
IgG2b anti-OVA titers than OVA plus CT-immunized mice
(Figure 6B, C). Mice immunized nasally with 30 or 100 mg OVA
plus CT showed no differences in IgG subclass responses (Figure
S2).
OVA-ps1(s) plus CT enhances mucosal inductive and
effector tissue B cell responses
To establish the source of the induced B cells responsible for the
enhanced mucosal IgA responses, mice were nasally immunized
with 30 mg OVA-ps1(s) or 100 mg OVA combined with CT;
separate groups were given 30 mg OVA-ps1(s) or OVA-ps1
alone. Three wks after primary immunization, a B cell ELISPOT
assay was performed to evaluate the source of OVA-specific IgA
and IgG responses in the NALT, cervical lymph nodes (CLNs),
submaxillary LNs (SMLNs), nasal passages (NPs), PPs, small
intestinal lamina propria (iLPs), spleens, and submaxillary glands
(SMGs) (Figure 7A, B). The OVA-ps1(s) plus CT-immunized
mice induced significantly greater (P#0.001) IgA responses in the
Figure 5. OVA-ps1(s) is 5 times more effective per molar basis than native OVA in stimulating immune Abs. Groups of C57BL/6 mice (9/
group) were immunized nasally with 30 mg OVA-ps1(s) alone, 30 mg OVA-ps1(s) plus cholera toxin (CT), or 100 mg OVA plus CT using the vaccination
schedule described in Fig. 4. A.–D. Although mice immunized with OVA-ps1(s) alone consistently produced less Ag-specific Abs, CT co-
administration enhanced anti-OVA endpoint titers than the 100 mg OVA plus CT-immunized group: A. serum IgG, B. serum IgA, C. fecal IgA, and D.
day 35 nasal wash IgA and IgG endpoint anti-OVA Ab titers. A kinetic analysis of the indicated time points is depicted from two experiments as mean
6 SEM; *P,0.001, **P#0.012 versus OVA plus CT-immunized mice; and
{ P,0.001 versus nasal wash titers from OVA-ps1(s) plus CT-immunized mice.
doi:10.1371/journal.pone.0036182.g005
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NALT and SMGs (Figure 7B) when compared to OVA plus CT-
immunized mice. For head and neck tissues, OVA-ps1(s) plus CT
immunized mice showed more enhanced IgA and IgG AFC
responses (P#0.001) than mice immunized with OVA-ps1. This
lack of AFC responses by mice given OVA-ps1 is consistent with
our previous findings showing that intact ps1 induces unrespon-
siveness, rather than active immunity, even when OVA-ps1 is co-
administered with potent adjuvants [25]. Thus, these studies show
OVA-ps1(s) in the absence of its SABD enhances Ag-specific B
cell responses in both the mucosal and systemic compartments.
OVA-Ps1(s) plus CT induces a mixed Th cell response
To assess the CD4
+ T cells supporting the observed elevated Ab
responses, cytokine analysis was performed. IFN-c and IL-17
secretion levels were similar between both groups of mice
immunized with OVA-ps1(s) plus CT and OVA plus CT
(Figure 8A). However, CD4
+ T cells from mice nasally immunized
with 30 mg OVA-ps1(s) plus CT showed significantly greater
(P,0.001) IL-4, IL-6, IL10, and IL-13 CFC responses than mice
nasally immunized with 100 mg OVA plus CT or from mice
immunized with 30 mg OVA-ps1(s) or 50 mg OVA-ps1 alone
(Figure 8B). Although Th2 cells are elevated, OVA-ps1(s) plus CT
immunization results in greater Th17 cell responses than mice
immunized with OVA plus CT.
Discussion
The mucosal immune system consists of the two functionally
distinct types of tissues: 1) inductive sites where naive B and T cells
come in contact with Ag; and 2) effector sites where activated B
and T cells, after Ag priming in inductive sites, express their
effector functions [31,32]. Inductive sites are where Ag is first
encountered and processed, and the initial induction of immune
and memory B and T cells occurs. In the gut, the PPs represent
inductive sites for the gut-associated lymphoreticular tissue
(GALT) [33,34], and similar lymphoid sites recently identified
for the upper airways in rodents are referred to as NALT [35,36].
These inductive tissues can be functionally and anatomically
separated into three distinctive areas: 1) the dome with a unique
lymphoepithelium; 2) the B cell follicles, usually containing one or
more germinal centers; and 3) the perifollicular or T cell-
dependent area. The dome region is covered by the epithelial
layer termed follicle-associated epithelium (FAE), and within this
epithelium are specialized epithelial cells or M cells that facilitate
luminal Ag sampling [36]. Some intestinal pathogens can infect
the host via M cells [9,10], such as reovirus types 1 and 3 [20,32]
and Salmonella [37].
Given certain pathogens can exploit M cells for infection
[9,10,20,32,37], and attenuated Salmonella vaccines are effective in
stimulating mucosal and systemic immune responses [38], we
questioned whether a soluble vaccine could be generated with the
M cell targeting capabilities of reovirus and Salmonella. Initial work
shows poly-L-lysine modification of ps1 enables mucosal DNA
vaccination [11,12], and such modification does not inhibit its
ability to bind to M cells [11]. Yet, a soluble fusion vaccine using
OVA-ps1 induces tolerance to both OVA and ps1, even in the
presence of potent adjuvants [25], suggesting poly-L-lysine
modification of ps1 may inadvertently interrupt or block its
SABD’s binding activity, making ps1 immunogenic [25]. Herein
this study, ablation of SABD clearly modified ps1’s immunoge-
nicity and elevated mucosal and systemic Ab responses to the
genetically fused Ag OVA subsequent nasal OVA-ps1(s) admin-
istration. OVA-ps1(s) was still found to bind to PP M cells in an
ileal loop assay, unlike native OVA, which did not appear to bind
to M cells. The cell binding by OVA-ps1(s) to the PP M cells
resembled our previous binding data for PP [26] and NALT [11],
suggesting it retained its ability to target mucosal inductive tissues.
Thus, in the absence of its SABD, OVA-ps1(s) retained its M cell
binding capacity despite losing its ability to bind to HeLa cells.
To test the influence of its SABD upon tolerance or
immunogenicity, experiments were conducted to measure induced
Ab responses to OVA when OVA-ps1(s) was used to immunize
mucosally in the absence or presence of co-administered adjuvant.
To determine if OVA-ps1(s) alone could induce significant anti-
OVA Ab responses without adjuvant, three 30 mg doses of OVA-
ps1(s) at weekly intervals were sufficiently effective to elicit
elevated serum IgG anti-OVA Ab levels. In fact, even after two
doses, these were markedly enhanced; however, fecal or nasal IgA
Abs levels were not greatly induced, suggesting that in the absence
of adjuvant the ps1(s) vaccine platform may be effective if the
desired endpoint only requires a systemic Ab response. Mice given
100 mg OVA alone produced serum IgG titers resembling mice
vaccinated with 10 mg OVA-ps1(s), and no mucosal Ab responses
could be detected (data not shown). Co-administration of CT with
OVA-ps1(s) amplified both the serum IgG and mucosal IgA anti-
OVA Ab responses significantly more than mice immunized with
OVA-ps1(s) alone. Importantly, when compared to native OVA
Figure 6. OVA-ps1(s) plus CT stimulates greater IgG subclass Ab titers than OVA plus cholera toxin (CT). The same groups of
immunized mice in Figure 5 were evaluated for their A. IgG1, B. IgG2a, and C. IgG2b subclass responses to OVA on days 21 and 28 post-primary
vaccination. The indicated time points are depicted from two experiments as mean 6 SEM; *P,0.001, **P,0.05 versus OVA plus CT-immunized mice.
doi:10.1371/journal.pone.0036182.g006
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PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e36182Figure 7. Nasal OVA-ps1(s)+cholera toxin (CT) enhances A. IgA and B. IgG antibody-forming cell (AFC) responses. C57BL/6 mice were
nasally immunized with OVA-ps1(s) alone, OVA-ps1alone, OVA-ps1(s) plus CT, or OVA plus CT. OVA-specific and total A. IgA and B. IgG AFCs were
measured by B cell ELISPOT conducted on day 21 post-primary immunization, and NALT, CLNs, SMLNs, nasal passages (NPs), PPs, small intestinal
lamina propria (iLP), spleens, and SMGs were evaluated. OVA-ps1(s) plus CT-immunized mice showed enhanced AFC responses in their CLNs,
submaxillary LNs (SMLNs), and submaxillary glands (SMGs) when compared to OVA plus CT-immunized mice. Values are the mean 6 SEM of AFC
responses taken from two experiments, *P#0.001, **P#0.01 vs. OVA plus CT-immunized mice.
doi:10.1371/journal.pone.0036182.g007
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required 5-fold less OVA than the 100 mg dose of OVA used to
stimulate equivalent systemic and mucosal Ab responses. While
serum IgG responses were similar in mice nasally immunized with
30 or 100 mg OVA, their fecal IgA responses did differ for the
100 mg-dosed mice, showing prolonged and greater SIgA anti-
OVA titers. At the 100 mg OVA dose, fecal and nasal wash IgA
anti-OVA Ab responses by mice immunized, either with native
OVA plus CT or OVA-ps1(s) plus CT, exhibited similar mucosal
IgA responses, and these were of similar magnitude obtained with
mice nasally immunized with OVA plus CT [25]. Thus, as
demonstrated here, vaccine targeting can enhance and can
certainly induce more rapid systemic and mucosal Ab responses.
Evaluation of the supportive Th cells for the OVA-specific Ab
responses revealed modest Th2-type production when OVA-
ps1(s) plus CT was used to immunize mice. Both IFN-c and IL-17
were markedly induced by OVA-ps1(s) plus CT-immunized mice
when compared to OVA plus CT-immunized mice. It was
recently shown that nasal CT immunization can stimulate IL-6-
and IL-17-producing CD4
+ T cells [39,40], and our results
confirmed this finding. In this regard, OVA-ps1(s) plus CT-
immunized mice showed elevated Th17 cell responses significantly
greater than OVA plus CT-immunized mice and provided a
method for potentially vaccinating against pathogens requiring
Th17 cells to resolve infections, such as with Streptococcus pneumoniae
[41] or Pseudomonas aeruginosa [42]. Although a mixed Th cell
response was induced, these data show OVA-ps1(s) in the
presence of CT can elicit an elevated Th17 cell response.
To begin to understand the mechanism of action by ps1(s),
additional analyses were performed to assess how OVA-ps1(s) can
Figure 8. Nasal OVA-ps1(s) stimulates mixed Th cell responses. OVA-ps1(s) plus cholera toxin (CT) enhances splenic OVA-specific Th2 and
Th17 cell responses when compared to mice nasally immunized with OVA-ps1(s) alone, OVA-ps1 alone, or with OVA plus CT-immunized mice. On
day 24 post-primary immunization, CD4
+ T cells were isolated and cultured in the presence of OVA or media for 2 days, and subsequently assessed for
A. IFN-c and IL-17 production by ELISA and B. IL-4, IL-6, IL-10, and IL-13 cytokine-forming cell (CFC) responses by T cell ELISPOT. Depicted are the
means (corrected for media values) 6 SEM of two experiments: * P,0.001 versus OVA plus CT-immunized mice.
doi:10.1371/journal.pone.0036182.g008
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efficient than with native OVA since usually 1.0 mg/ml was
required for native OVA [43] rather than the 50 mg/ml OVA-
ps1(s) used in this study, and when this lesser dose (50 mg/ml) of
native OVA was used, suboptimal priming was obtained. This in
vitro finding further confirmed our in vivo results showing the
improved efficiency of using OVA-ps1(s). Unlike intact OVA-
ps1, which failed to induce a proliferative response, OVA-ps1(s)
could stimulate DO11.10 CD4
+ T and OT-I CD8
+ T cells to
proliferate, unlike OVA-ps1, as previously demonstrated for
CD4
+ T cells [25,26]. OVA-ps1 also failed to stimulate CD8
+ T
cells, a finding not previously described. In fact, OVA-ps1 was
found to be tolerogenic and stimulated the production of IL-10
[25–29] or TGF-b [26,27] and suppressed IFN-c and IL-17 [25–
28]. Since OVA-ps1(s) lacked the SABD, an immunostimulatory
response was induced, suggesting the SABD also contributes to
tolerance induction.
In conclusion, the collective data demonstrate OVA-ps1(s) is
immunostimulatory in the absence of binding sialic acids, unlike its
parent molecule, OVA-ps1, which contains its SABD and results
in tolerance induction. In fact, ps1-mediated tolerance has been
observed with other Ags, including proteolipid protein peptide
[27] and myelin oligodendrocyte glycoprotein [28,29]. Conse-
quently, OVA-ps1(s) still retains its M cell targeting moiety to
enable more effective mucosal vaccination than OVA alone. Such




All animal care and procedures were in accordance with
institutional policies for animal health and well-being and
approved by Montana State University Institutional Animal Care
and Use Committee under protocol 52.
Construction and expression of OVA-ps1(s)
OVA-ps1(s) is a deletion mutant of OVA-ps1 [25] encom-
passing the entire OVA gene fused to the last 207 amino acids of
ps1, leaving a minimal binding subunit that includes the
trimerizing domain and H (Figure 1A). OVA was amplified with
a5 9 primer featuring an EcoR1 site and an ATG codon and a 39
Sal1 primer. The upstream primer for ps1 contained a SalI site
designed to frame the OVA; the downstream primer contained a
KpnI primer designed to frame the fused protein to the His-tag
present in the Pichia pastoris expression vector pPICB. The PCR
products were gel-purified and cloned into a topocloning vector.
The inserts were then excised by cutting with the appropriate pairs
of restriction enzymes (New England Labs, Beverly, MA) and gel-
purified again. Finally, the yeast expression vector was cut with
EcoRI and KpnI. A tripartite ligation was set up to ligate: 1) the
‘‘passenger Ag’’ (OVA), as an EcoRI-SalI fragment; 2) the
‘‘transporter,’’ as a SalI-KpnI fragment; and 3) the vector cut with
EcoRI and KpnI. The junction between the ‘‘passenger Ag’’ and the
‘‘transporter’’ featured a flexible linker (Gly-Arg-Pro-Gly) to
minimize steric hindrance between the components. To construct
GFP-ps1, the gene encoding for ps1 was amplified with a 59
EcoRI primer and a 39 SalI primer, gel-purified, cloned into E.coli
via a topocloning vector, excised with EcoRI-SalI, repurified, and
cloned into the P. pastoris pPICZA expression vector cut with
EcoRI-SalI. The resulting construct was modified by inserting an
EcoRI fragment containing a GFP gene that was amplified from
pLANTERN (Gibco-BRL) as a template. Primers were designed
to frame GFP into ps1 and the fusion into the His-tag of the
vector. To construct GFP-ps1(s), the same strategy was followed,
but only the appropriate deletion primer was designed to amplify
the last 207 amino acids of the ps1. The resulting constructs were
sequenced and expressed in the yeast P. pastoris, according to the
manufacturer’s directions (Invitrogen Corp., Carlsbad, CA).
Recombinant proteins were extracted from yeast cells by a bead-
beater (Biospec Products, Bertlesville, OK) and purified on a
Talon metal affinity resin (BD Biosciences, Palo Alto, CA),
according to manufacturer’s instructions. Proteins were assessed
for purity and quality by Coomassie-stained polyacrylamide gel
electrophoresis. OVA-ps1(s) migrated as a single band with the
expected MW ,68,300 Da.
Cell binding assays
L929 cells (ATCC, CCL-1, Manassas, VA) and HeLa cells
(ATCC, CCL-2) were grown in a complete medium (CM): RPMI
medium supplemented with FBS (Atlanta Biologicals, Atlanta,
GA), 1 mM nonessential amino acids, 1 mM sodium pyruvate,
1 mM HEPES, 100 mg/ml penicillin, and 100 mg/ml streptomy-
cin. DCs were enriched from head and neck lymph nodes and
spleens, similar to that previously described [44]. Briefly, tissues
were subjected to collagenase (50 U/ml Type IV; Sigma-Aldrich,
St. Louis, MO) digestion+DNAse (0.8 U/ml; Promega, Madison,
WI) in teflon flasks with gentle stirring for 30 min at 37uC. The
digested tissues were passed through Nitex (Fairview Fabrics,
Hercules, CA) and incubated in CM at 37uC for 30 min. Cell
suspensions were washed in CM and then subjected to density
gradient centrifugation using a modified technique [44]. Total
lymphocytes were resuspended in 2.0 ml of Hank’s Balanced Salt
Solution (HBSS; GIBCO-Invitrogen Corp.) and then added to
1.0 ml Optiprep
TM (Axis-Shield PoC AS, Oslo, Norway) and
mixed gently. Cells were then layered onto the density gradient
with a 1:3.2 (14.3%) solution of diluent, which consisted of 0.88%
NaCl, 1.0 mM EDTA, and 0.5% (w/v) BSA, and 10 mM Hepes-
NaOH, pH 7.4) and Optiprep
TM. The gradient was then topped
with 3.0 ml of HBSS. Lymphocytes were subjected to density
gradient centrifugation for 15 min at 20uC. DCs were removed
from the top of the Optiprep gradient and washed in CM.
Typically, DCs were enriched to .85% purity, as evaluated by
immunofluorescent staining with anti-CD11c (B–D Pharmingen,
San Diego, CA) and anti-CD205 (DEC205; Serotec, Inc., Raleigh,
NC) mAbs.
L and HeLa cells (3610
4) and DCs (3610
5) were resuspended in
200 ml of FACS buffer (Dulbecco PBS+2% FBS) containing
equimolar GFP concentration relative to 10 mg of GFP-ps1:
7.5 mg of GFP-ps1(s) and 3.9 mg GFP. These were incubated on
ice for 20 min. Cells were washed once with 3 ml of FACS buffer
and resuspended in FACS buffer and subjected to FACS analysis
on a FACSCalibur flow cytometer (BD Biosciences).
Immunofluorescent detection of OVA-ps1(s) binding to
M cells
An ileal method was used to detect OVA-ps1(s) binding to PP
M cells similar to that previously described [45]. Ileal loops were
injected with 200 mg OVA-ps1(s) or OVA and incubated for 1 hr;
ileal loops were removed and injected with OCTH cryoembedding
media (Sakura Finetek, Torrance CA) to distend the lumen. The
OCT filled loop was embedded in OCT, snap frozen with dry ice,
cooled in 2-methylbutane, and sectioned into 5 mm using a
cryostat. Frozen sections were picked up on positive charge slides,
air dried at room temperature overnight, fixed at room
temperature in 75 ml acetone/25 ml absolute ethanol for
5 minutes, and rinsed immediately after fixation with 3 changes
of rinse buffer (Dulbeccos PBS/0.025% Tween 20). Sections were
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stained with 8 mg/ml Ulex Europaeus agglutinin 1 conjugated to
FITC (UEA-1-FITC; Vector Laboratories, Burlingame, CA) in
rinse buffer for 30 min at room temperature. To block UEA-1
binding, 8 mg/ml UEA1-FITC in 300 mM L-fucose was incubat-
ed overnight at 4uC before applied to a section, as described
above. Sections were rinsed and then blocked with 10% normal
goat serum/1.5% mouse serum in rinse buffer for 30 min followed
by Streptavidin/Biotin blocking kit (Vector Laboratories). A
biotinylated rabbit anti-OVA Ab (5 mg/ml; Sigma-Aldrich) diluted
in 10% goat/2.5% mouse serum in rinse buffer was applied to
sections for 30 min at room temperature. The negative control
used was 5 mg/ml biotinylated rabbit IgG in same diluent and
served as primary Ab. Sections were rinsed, then incubated for
30 min at room temperature with 2 mg/ml Streptavidin-AlexaH
Fluor 594 (Molecular Probes/Invitrogen, Eugene, OR) diluted in
rinse buffer, and then rinsed and cover slipped with Prolong Gold
antifade reagent with DAPI (Molecular Probes/Invitrogen).
Assessment of OVA-ps1(s)’s proliferative capacities
HNLN and splenic DCs were isolated, as described above, via
Optiprep
TM gradient centrifugation. The DCs were pulsed
overnight with media, 50 mg/ml OVA-ps1, 50 mg/ml OVA-
ps1(s), 50 mg/ml OVA, or 1.0 mg/ml OVA (grade V; Sigma-
Aldrich) [25,43], and the next day, DCs were washed in CM.
DO11.10 CD4
+ T cells were isolated by negative selection (Dynal
Mouse CD4 Negative Isolation Kit, Invitrogen), as were OT-I
CD8
+ T cells (Dynal CD8 Negative Isolation Kit, Invitrogen), and
each was labeled with 1.25 mM carboxy-fluorescein diactetate
succinimidyl ester (CFDA; Molecular Probes-Invitrogen) in RPMI
for 5 min at room temperature in the dark and then washed three
times. The labeled DO11.10 CD4
+ and OT-I CD8
+ T cells were
added to the Ag-pulsed DCs at 2:1 ratio, and lymphocytes were
cultured for 4 days. After culture, labeled DO11.10 CD4
+ and
OT-I CD8
+ T cells were evaluated for extent of their proliferation
by flow cytometry.
Mice and immunizations
C57BL/6N and BALB/c mice (Frederick Cancer Research
Facility, National Cancer Institute, Frederick, MD) and transgenic
DO11.10 mice [25] were used throughout this study. All mice
were maintained at Montana State University Animal Resources
Center under pathogen-free conditions in individually ventilated
cages under HEPA-filtered barrier conditions and fed sterile food
and water ad libitum. The mice used were 6 to 8 wks of age and
free of bacterial and viral pathogens, as determined by Ab
screening and histopathologic analysis of major organs and tissues.
All animal studies were approved by the MSU Institutional
Animal Care and Use Committee.
C57BL/6 mice (5 per group) were nasally immunized with 10,
30, or 100 mg of OVA-ps1(s), OVA-ps1, or OVA (Sigma-
Aldrich) without and with 2.0 mg CT adjuvant on days 0, 7, and
14. Blood (from saphenous vein) and mucosal samples were
collected weekly beginning day 14. Fecal extractions and vaginal
washes were performed, as previously described [25].
Ab detection assays
Serum and fecal samples were evaluated for anti-OVA endpoint
Ab titers by ELISA similar to that previously described [25], using
purified OVA (Grade V, Sigma-Aldrich) as the coating Ag.
Specific reactivity to OVA was determined using HRP conjugates
of goat anti-mouse IgG-, IgG1-, IgG2a-, IgG2b-, and IgA-specific
Abs (1.0 mg/ml; Southern Biotechnology Associates, Birming-
ham, AL), and ABTS (Moss Inc., Pasadena, CA) enzyme
substrate. The absorbencies were measured at 415 nm on an
ELx808 microplate reader (Bio-Tek Instruments). Endpoint titers
were expressed as the reciprocal dilution of the last sample
dilution, giving an absorbance of 0.1 OD units above the OD415
of negative controls after 1 h incubation.
To assess OVA-specific and total Ab-forming cell (AFC)
responses, the B cell ELISPOT method was used [11,13,26].
Single cell suspensions were prepared from the CLNs, SMLNs,
NALT, SMGs, NPs, iLP, PPs, and spleens of mice immunized
with OVA plus CT, OVA-ps1, and OVA-ps1(s) with and
without CT. Mucosal inductive tissues and spleens were isolated
by conventional methods, similar to those previously described
[11,13,25]. Briefly, dounce homogenization of tissues was
performed, and mononuclear cells were obtained subsequently
by Lympholyte M (Accurate Chemical & Scientific Corporation,
Westbury, NY) density gradient centrifugation and yielded .95%
viability, as determined by trypan blue exclusion. Mucosal effector
lymphocytes were isolated, similar to that previously described,
using collagenase digestion methods [25,27] and also yielded
.95% viability, as determined by trypan blue exclusion.
Lymphocytes were incubated on OVA-coated, mixed cellulose
ester membrane-bottom microtiter plates (MultiScreen-HA; Milli-
pore, Bedford, MA). For total IgA or IgG AFC responses, wells
were coated with 5 mg/ml goat anti-mouse IgA or IgG Abs
(Southern Biotechnology Associates) in sterile PBS. Following
overnight incubation at 37uC and a wash step, HRP-labeled anti-
IgG or anti-IgA Abs were added for overnight incubation at 4uC
in a humidified chamber. Following a wash step, individual wells
were developed by adding 3-amino-9-ethylcarbazole substrate
(AEC; Moss), and the reaction was stopped with H2O. Wells were
allowed to dry overnight, and AFCs were enumerated, using a
Stereozoom 5 dissecting microscope (Leica, Buffalo, NY).
Cytokine detection assays
Splenic lymphocytes were isolated, as described above, by
Lympholyte-M (Accurate Chemical & Scientific Corporation)
gradient centrifugation. CD4
+ T cells were isolated by negative
selection as described above. An aliquot of 2610
6 CD4
+ T cells
was cultured for 72 h (37uC, 5% CO2) with an equal number of
splenic feeder cells (T cell-depleted, mitomycin C-treated) in the
presence or absence of 1 mg/ml OVA [25,26]. Stimulated
lymphocytes were evaluated by IFN-c- and IL-17A-specific ELISA
[25,27,28] and IL-4-, IL-6-, IL-10-, and IL-13-specific ELISPOT
assays to enumerate cytokine-forming cell (CFC) responses, as
described previously [25].
Statistical analysis
The two-way ANOVA (Holm-Sidak method) test was used to
evaluate the differences among groups in dose-dependent
experiments. The one-way ANOVA test was used to evaluate
the differences among experimental parameters in each experi-
ment.
Supporting Information
Figure S1 Dose and kinetic analysis of nasal OVA
immunization to stimulate immune Abs. Groups of
C57BL/6 mice (5–8/group) were immunized nasally with 30 mg
OVA alone, 100 mg OVA alone, 30 mg OVA plus cholera toxin
(CT), or 100 mg OVA plus CT using the vaccination schedule
described in Fig. 4. A. serum IgG, B. serum IgA, C. fecal IgA, and
D. day 35 nasal wash IgG and IgA endpoint anti-OVA Ab titers
were determined by OVA-specific ELISAs. It was found that
100 mg OVA plus CT induced optimal mucosal IgA responses;
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mice; and
{ P#0.013 vs. 100 mg OVA-immunized mice.
(TIF)
Figure S2 IgG subclass anti-OVA responses by mice
immunized with OVA plus CT. The OVA plus CT-
immunized mice in Figure S1 were evaluated for their A. IgG1,
B. IgG2a, and C. IgG2b subclass responses to OVA on days 21
and 28 post-primary vaccination as mean 6 SEM. There were no
statistical differences between immunization groups measured at
day 21 or 28.
(TIF)
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